BPMC - Tasty Short BPMC
With indexes showing bearish potential, this is quite a tasty looking short setup here as this stock has just had a big earnings gap up today.
This appears to be a 1:1.618 ABC with an Ending Diagonal.
Ending Diagonal is is just an ascending wedge at the end of an impulse wave.
Notice the be
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.28 EUR
−64.81 M EUR
491.51 M EUR
63.30 M
About Blueprint Medicines Corporation
Sector
Industry
CEO
Kathryn Haviland
Website
Headquarters
Cambridge
Founded
2008
FIGI
BBG01TNWK140
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
💊 Blueprint Medicines: Positive Momentum and Growth Prospects! 📊 Analysis NASDAQ:BPMC :
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to i
BPMC - head and shoulder championThis chart seems to love itself. Infatuated with its very own "Head and Shoulders" multiple times looking back on the daily!
Waiting for this one to fill out completely before entering puts. No entry without confirmation. Inside channel, recent bounce off weekly resistance point forming its head. W
BPMC, enters Downtrend as Momentum drops below 0 level on Nov 18This indicator may be signaling that BPMC's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron's A.I.dvisor backtested 79 similar cases where BPMC's Momentum Indicator fell below
BPMC: BUY DIPS 50% gains // SWING trade (STOCKS)Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
$BPMC can rise in the next daysContextual immersion trading strategy idea.
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy.
The share prose rose after the company had announced the deal with pha
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
The current price of 1BPMC is 89.52 EUR — it has increased by 14.65% in the past 24 hours. Watch BLUEPRINT MEDICINES CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BLUEPRINT MEDICINES CORP stocks are traded under the ticker 1BPMC.
1BPMC stock has risen by 15.06% compared to the previous week, the month change is a 15.06% rise, over the last year BLUEPRINT MEDICINES CORP has showed a 15.06% increase.
We've gathered analysts' opinions on BLUEPRINT MEDICINES CORP future price: according to them, 1BPMC price has a max estimate of 147.95 EUR and a min estimate of 73.53 EUR. Watch 1BPMC chart and read a more detailed BLUEPRINT MEDICINES CORP stock forecast: see what analysts think of BLUEPRINT MEDICINES CORP and suggest that you do with its stocks.
1BPMC stock is 12.78% volatile and has beta coefficient of 1.37. Track BLUEPRINT MEDICINES CORP stock price on the chart and check out the list of the most volatile stocks — is BLUEPRINT MEDICINES CORP there?
Yes, you can track BLUEPRINT MEDICINES CORP financials in yearly and quarterly reports right on TradingView.
BLUEPRINT MEDICINES CORP is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
1BPMC earnings for the last quarter are 0.0092 EUR per share, whereas the estimation was −0.45 EUR resulting in a 102.06% surprise. The estimated earnings for the next quarter are −0.41 EUR per share. See more details about BLUEPRINT MEDICINES CORP earnings.
BLUEPRINT MEDICINES CORP revenue for the last quarter amounts to 138.11 M EUR, despite the estimated figure of 143.72 M EUR. In the next quarter, revenue is expected to reach 151.67 M EUR.
1BPMC net income for the last quarter is 458.47 K EUR, while the quarter before that showed −48.26 M EUR of net income which accounts for 100.95% change. Track more BLUEPRINT MEDICINES CORP financial stats to get the full picture.
No, 1BPMC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 649 employees. See our rating of the largest employees — is BLUEPRINT MEDICINES CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BLUEPRINT MEDICINES CORP EBITDA is −146.39 M EUR, and current EBITDA margin is −38.47%. See more stats in BLUEPRINT MEDICINES CORP financial statements.
Like other stocks, 1BPMC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BLUEPRINT MEDICINES CORP stock right from TradingView charts — choose your broker and connect to your account.